a 01

A 83-01 (ALK5 Inhibitor IV) is an inhibitor of the TGF-β type I receptors ALK5, ALK4, and ALK7 (IC50=12/45/7.5 nM). A 83-01 promotes the reprogramming of mouse fibroblasts into iPSCs. A 83-01 can be used in organoid cultures.

IMM-01 is a novel class of small-molecule agonists of the mammalian Diaphanous (mDia)-related formins, which act downstream of Rho GTPases to assemble actin filaments, and their organization with microfilaments to establish and maintain cell polarity during migration and asymmetric division. GTP-bound Rho activates mDia family members by disrupting the interaction between the DID and DAD autoregulatory domains, which releases the FH2 domain to modulate actin and microtubule dynamics[1].

DVR-01 is an HBV capsid inhibitor and can be used in studies about the treatment of Hepatitis B virus (HBV) infection and related conditions.

AMC-01 has potential antiviral activity and induces dose- and time-dependent inactivation of eIF2-α via phosphorylation of serine residue 51. AMC-01 can be used to study atherosclerosis and Parkinson's syndrome.

HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM).HTH-01-091 inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 can be used to study breast cancer.

HTH-01-015 is a selective NUAK1 inhibitor (IC50=100 nM).

HG-9-91-01 (SIK inhibitor 1) is a potent and highly selective salt-inducible kinase (SIKs) inhibitor with IC50s of 0.92 nM, 6.6 nM and 9.6 nM for SIK1, SIK2 and SIK3respectively.

IITZ-01 is potent autophagy inhibitor with single-agent anticancer activity ( IC50 of 2.62 μM for PI3Kγ.)

BIO-013077-01 is a potent TGFbeta family type I receptors antagonist.

NICE-01 (AP1867-PEG2-JQ1; AP-PEG2-JQ1) is a bifunctional compound that facilitates the nuclear import of cytosolic cargoes by leveraging the nuclear-localized bromodomain-containing protein 4 (BRD4) as a carrier for their co-import and subsequent nuclear entrapment [1].

HG-7-85-01 is a type II ATP competitive inhibitor targeting wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. It effectively inhibits T315I mutant Bcr-Abl kinase, as well as KDR and RET kinases with IC50 values of 3 nM, 20 nM, and 30 nM, respectively. In contrast, HG-7-85-01 exhibits weak or no inhibition towards other kinases (IC50 >2 μM). Furthermore, this compound inhibits cell proliferation through the induction of apoptosis and by impeding cell-cycle progression.

DL-01 is a drug-linker conjugate for antibody-drug conjugates (ADCs), utilized in the synthesis of ADCs [1].

DM-01 is a potent and selective inhibitor of EZH2. DM-01 can be used to study diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and SNF5/INI-1/SMARCB1 gene-associated solid tumours.

Zt-12-037-01 is a ATP competitive STK19 inhibitor（IC50 values of 23.96 nM and 27.94 nM for STK19 (WT) and STK19 (D89N),respectively).

OATD-01 is a highly active inhibitor of both Chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase).

A 83-01 sodium salt is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC 50 s of 12 nM, 45 nM and 7.5 nM against the ALK5, ALK4 and ALK7 induced transcription, respectively [1].

MYF-01-37 (1-[3-Methyl-3-[3-(trifluoromethyl)anilino]pyrrolidin-1-yl]prop-2-en-1-one) is a novel covalent TEAD inhibitor.

JH-X-119-01 is a highly potent and selective covalent inhibitor of IRAK-1.

TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC50s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively.

BSJ-01-175 is a selective and potent covalent inhibitor of CDK12/13. BSJ-01-175 is significantly selective for cancer cells, exhibits potent inhibition of phosphorylated RNA polymerase II, and significantly downregulates CDK12 target genes.

A 77-01 is a potent inhibitor of TGF-(beta) type I receptor superfamily activin-like kinase ALK5 with IC50 of 25 nM.

NMO-IgG blocker A-01 is a idiotype-specific blocker of neuromyelitis opticaimmunoglobulin g (nmo-igg) binding to aquaporin-4 (aqp4)

HTH-01-091 TFA, a potent and selective inhibitor of maternal embryonic leucine zipper kinase (MELK), exhibits an IC50 of 10.5 nM. Besides its primary target, it also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2, positioning it as a promising agent for breast cancer research [1].

WU-FA-01, a hydrogenated derivative of WU-FA-00, functions as an antibacterial agent with robust activity against Gram-positive strains and possesses anti-inflammatory properties [1].

CCCI-01（Centrosome Clustering Chemical Inhibitor-01） is a centrosome cluster inhibitor. CCCI-01 has anticancer activity, induces apoptosis, and can be used in the study of non-cross-resistant anticancer compounds that block centrosome clustering.

HG-7-85-01-NH2, as the ligand for SNIPER(ABL)-033, effectively induces the reduction of BCR-ABL protein. This is achieved through SNIPER(ABL)-033, which connects HG-7-85-01 (an ABL inhibitor) to an LCL161 derivative (an IAP ligand) using a linker, demonstrating a DC50 value of 0.3 μM [1].

JH-X-119-01 hydrochloride is a potent and selective inhibitor of interleukin-1 receptor-associated kinases 1 (IRAK1). It effectively alleviates lipopolysaccharide (LPS)-induced sepsis in mice.

(3S,4S)-A2-32-01, a less active (S,S)-enantiomer of A2-32-01. A2-32-01 is a potent caseinolytic protein proteases (ClpP) inhibitor .

HPN-01 (IKK inhibitor XII) is a selective IKK inhibitor that inhibits IKK-α, IKK-β, and IKK-ε. HPN-01 reduces the severity of the disease, attenuates the immune imbalance, and prolongs the lifespan of mice in a model of autoimmune encephalomyelitis, and can be used to study immune disorders.

iGOT1-01 is an effective inhibitor of glutamate oxaloacetate transaminase 1(GOT1) . iGOT1-01 has IC50s of 84.6 μM and 11.3 μM in GOT1/MDH1 assay and GOT1/GLOX/HRP assay, respectively. iGOT1-01 can be used in anti-cancer studies.

HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 of 20.3 nM).

MW01-2-151SRM is a novel small molecule inhibitor of microglia activation that crosses the blood-brain barrier, has anti-neuroinflammatory effects, attenuates the up-regulation of glial cytokines in models of neuroinflammation, and can be used in studies of traumatic brain injury, Alzheimer's disease, and alginate toxicity.

RV01 is a novel quinoline-substituted analogue of resveratrol that inhibits DNA damage, reduces ethanol-induced acetaldehyde dehydrogenase (ALDH2) mRNA expression, and has hydroxyl radical scavenging activity. rV01 reduces iNOS expression and has anti-neuroinflammatory effects. rV01 reduces tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) mRNA levels and secretion. RV01 reduced tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) mRNA levels and secretion, inhibited lps-induced ROS production and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, decreased toll-like receptor 4 (TLR4) protein expression, and inhibited lps-induced activation of mitogen-activated protein kinase (MAPK) and nuclear transcription factor-кB (NF-кB) signaling pathways.

Xenopsin(2TFA) is a neurotensin-like octapeptide previously isolated from amphibian skin.

Rac1 Inhibitor W56 acetate(1095179-01-3 free base) is a peptide comprising residues 45-60 of the guanine nucleotide exchange factor (GEF) recognition/activation site of Rac1. Rac1 Inhibitor W56 acetate(1095179-01-3 free base) selectively inhibits Rac1 interaction with Rac1-specific GEFs TrioN, GEF-H1 and Tiam1.

LYS01 free base is a new lysosomal autophagy inhibitor.

LY3295668 (AK-01) is a selective inhibitor of Aurora A with Kis of 0.8 nM and 1038 nM for Aurora A and B, respectively.

HJ-PI01 (HJ-PI01) is a Pim-2 inhibitor. HJ-PI01 (HJ-PI01) induces apoptosis and autophagic cell death in triple-negative human breast cancer.

K 01-162 binds and destabilizes AβO (β-amyloid), with an EC50 of 80 nM.

T16Ainh-A01 is a potent inhibitor of TMEM16A Chloride channel, inhibiting TMEM16A-mediated chloride currents (IC50 of 1 µM),and functions as a calcium-activated chloride channel (CaCC).

CCD Lipid01 (LP-01) is a lipid membrane that can be used to deliver biologically active agents .

rTRD01 is a TDP-43 ligand that selectively binds to the RRM1 and RRM2 domains of TDP-43, exhibiting a dissociation constant (Kd) of 89 µM for TDP-43 102–269. This compound is capable of partially disrupting the interaction between TDP-43 and the hexanucleotide RNA repeat associated with the c9orf72 gene, which is implicated in certain neurodegenerative diseases. rTRD01 holds potential for use in neurodegenerative disease research [1].

PAT1inh-B01, a selective SLC26A6 inhibitor, impedes PAT1 (a Cl-/HCO3- exchanger) activity, with an IC50 of 350 nM, effectively inhibiting anion exchange. It also obstructs fluid absorption in the small intestine and is utilized in the study of small intestinal hyposecretory disorders [1].

Synucleozid hydrochloride is a potent the SNCA mRNA inhibitor that encodes α-synuclein protein (IC50=1.5 μM), has the potential for the investigation of Parkinson’s disease.

BZAD01 is a selective NMDA NR1A/2B receptor antagonist.

THK01, a potent ROCK2 inhibitor, exhibits IC50 values of 5.7 nM for ROCK2 and 923 nM for ROCK1, respectively. It effectively targets the ROCK2-STAT3 signaling pathway to inhibit breast cancer metastasis, making it valuable for breast cancer research [1].

YM-01 Tosylate, a potent antitumor agent, selectively targets cancer cells and overcoming tamoxifen resistance.

3HOI-BA-01 is a mammalian targeting effective rapamycin activation inhibitor.

KX-01-191 is a tin-precursor.

PI3KD/V-IN-01 is a potent ATP-competitive PI3Kδ/Vps34 dual inhibitor.